March 7, 2022 7:53am

Could it be a positive signal for some indications of our universe of cell and gene therapy sector equities?

Pre-open indications: 6 SELLs indications, 6 BUYs Indication and 1 pimp/pump/promote

News: Agenus (AGEN +$0.04) and Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that they have entered into a clinical collaboration and supply agreement to combine TRUV’s TG mutant KRAS cancer vaccines with AGEN’s clinically validated and FDA approved QS-21 STIMULON adjuvant.

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Only the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

 

Dow futures are DOWN -0.74% (-248 points), S&P futures are DOWN -0.62% (-27 points) and NASDAQ futures are DOWN -0.73% (-101 points)

 

U.S. equity futures pointed to a negative open on Monday morning as investors remain rattled by the ongoing war in Ukraine,

European stocks tanked after news that the U.S. and European allies are considering a ban on Russian oil imports,

Asia-Pacific stocks closed lower, with Hong Kong’s Hang Seng index dropping more than 3.5% to lead regional losses.

 

Henry’omics:

Indexes fell on Friday despite a stronger-than-expected jobs report as Ukraine weighed on sentiment.

Last week, the Dow shed -1.3% and S&P 500 slid -1.3% while the Nasdaq lost roughly -2.88%.

Old word is back in the vocabulary, “stagflation — a period of slow economic growth and high unemployment coupled with high inflation.”

For the Nasdaq, 12,587,88 marks the Feb. 24 low, but the 13,000 level will be key. That would undercut several recent lows or closing lows going back 10 months.

 

RegMed Investors’ (RMi) closing bell: “the advance/decline line pooped the stoop. Strong jobs report overshadowed Ukraine killing fields, which also initiated risk aversion and a cell and gene therapy sector flight to the downside” …  https://www.regmedinvestors.com/articles/12328

Ebb and flow –

·         March – 3 negative and 1 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes

 

 

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... bluebird (BLUE) added - 22 total to date

The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW) … https://www.regmedinvestors.com/articles/12306

UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies https://www.regmedinvestors.com/articles/12320 - added commentary

 

 

Companies in my headlights – It’s your decision; I provide ideas and context of possible indications:

BUY:

Agenus (AGEN) closed down -$0.05 to $2.91 with a positive pre-open indication of =$0.04 or +1.37% on collaboration news (in title)

Cellectis SA (CLLS) closed down -$0.26 after Thursday’s -$0.36 after Wednesday’s -$0.18 with a positive +$0.02 or +0.57% and earnings release,

Fate Therapeutics (FATE) closed down -$0.58 with a positive +$0.69 or +2.09% pre-open indication.

Homology Medicine (FIXX) closed down -$0.24 with a positive +$0.20 or +6.63% pre-open indication.

Ionis Pharmaceuticals (IONS) closed down -$0.94 with a positive +$0.30 or +0.93% pre-open indication.

MiMedx (MDXG) closed down -$0.15 with a positive +$0.24 or +4.93% pre-open indication.

 

SELL:

Global Blood Therapeutics (GBT) closed down -$0.45 with a negative pre-open indication of -$0.08 or -0.29%

bluebird Bio (BLUE) closed down -$0.21 to $5.00 with a negative pre-open indication -$0.79 or -15.90% post earnings’ report.

CRISPR Therapeutics (CRSP) closed down -$1.00 after Thursday’s -$4.59, Wednesday’s +$1.34, Tuesday’s -$3.93 and last Monday’s +$1.64 with a negative pre-open indication -$0.69 or -1.30% post earnings’ report.

 

Maintaining SELL:

Beam Therapeutics (BEAM closed down -$3.75 after Thursday’s -$6.40 after Wednesday’s +$0.70, Tuesday’s -$4.85 and Monday’s -$3.60) with a negative pre-open indication -$0.55 or -0.86%

Editas Medicine (EDIT -$0.68 after Friday’s -$0.41 after Wednesday’s -$0.34, Tuesday’s +$0.37 after Monday’s $0.22) with a pre-open indication -$0.16 or -1%.

Intellia Therapeutics (NTLA -$5.93 after Thursday’s -$13.42 after Wednesday’s +$4.54, Tuesday’s -$19.00 and last Monday’s +$2.49) with a positive pre-open indication -$0.14 or -0.22%

 

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed down -$0.4 after Thursday’s +$0.25 with 487 shares traded, Wednesday’s +$0.34 with 649 shares traded, Tuesday’s -$0.04 with 4,359 shares traded and last Monday’s +$0.37 with 687 shares traded …

WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?

·         Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.

 

The BOTTOM LINE: Any which way ... are we headed back to some strength and more loser indications as those oversold equities become targets.

Don't get sucked in by short-lived gains in this sh*t market; “the Nasdaq has had four 2%-plus gains since the Jan. 28 low, three of which were more than 3%. But the Nasdaq has trended lower over that time, especially since Feb. 9.” <IBD>

Negative closes on Thursday and Friday – that’s three (3) for this new month of March.

Earnings’ reporting on the horizon:

·         Athersys (ATHX), Tuesday, 3/15

·         Cellectis SA (CLLS) Thursday, 3/22

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.